imaGenes achieves Roche NimbleGen CSP-status for ChIP-chip application

Dec 16 2009

Roche NimbleGen (Pink Sheets:RHHBY) (SWX:RO) (SWX:ROG) has announced that imaGenes GmbH, a Berlin-based genomics & proteomics specialist, has achieved status as a Certified Service Provider (CSP) of NimbleGen microarrays for Chromatin Immunoprecipitation (ChIP-chip). imaGenes GmbH has passed a rigorous ChIP-chip certification to officially become part of the Roche NimbleGen Certified Service Provider Program. As a CSP, they will be responsible for processing customer samples for DNA-protein interactions and chromatin structure. They have been certified at their lab in Berlin, Germany using the complete NimbleGen Dual-Color workflow which includes the high-resolution MS 200 Microarray Scanner.

“The precision and flexibility of the NimbleGen Arrays was the decisive factor for imaGenes to immediately apply to Roche NimbleGen’s Certified Service Provider Program and to use the technology in large scale for the “Epifood” project,” says Dr. Steffen Hennig, Director Bioinformatics & Services at imaGenes. “The NimbleGen CSP-status will position imaGenes at the international forefront of microarray application specialists”.

“Roche NimbleGen is pleased to welcome imaGenes GmbH as our first global certified service provider for the ChIP-chip application. imaGenes’ microarray team has more than five years of experience with the technology of NimbleGen Arrays and their close ties with the former RZPD (German Science Center for Genome Research) and key opinion leaders brings an exceptional level of credibility to our core business of academic researchers. We anticipate that our relationship with imaGenes GmbH will further expand our business in the German market and fuel the basic research that is vital to the personalized healthcare pipeline," said Dr. Gerd Maass, CEO of Roche NimbleGen, Inc.